Gemcitabine and mitomycin C in advanced pancreatic cancer: a single-institution experience

Tuinmann, Gert; Hegewisch‐Becker, Susanna; Zschaber, R.; Kehr, Andreas; Schulz, J; Hossfeld, Dieter K.

doi:10.1097/01.cad.0000131683.29260.d1

Cited by 11 publications

(7 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…GEM is currently the first-line treatment for advanced pancreatic cancer, and it acts by inhibiting tumor cell proliferation and inducing apoptosis [22-25]. Prior to determining the effects of GEM on miR-214, we examined the effect of GEM on cell viability at 24, 48 and 72 hrs using the CCK-8 assay.…”

Section: Resultsmentioning

confidence: 99%

Dysregulation of miR-15a and miR-214 in human pancreatic cancer

et al. 2010

View full text Add to dashboard Cite

BackgroundRecent reports indicate that microRNAs (miRNAs) play a critical role in malignancies. However, the role that miRNAs play in pancreatic cancer remains to be determined. The purpose of this study was to investigate aberrantly expressed miRNAs in pancreatic cancer tissues and demonstrate their roles in disease progression.ResultsWe detected the expression patterns of miRNAs in 10 pancreatic cancer tissues and their adjacent benign tissues by quantitative real time-PCR (qRT-PCR) and found that miR-15a and miR-214 were dysregulated in the tumor samples. This is the first time that miR-214 has been identified as aberrantly expressed in pancreatic cancer. In vitro experiments showed that overexpression of miR-15a inhibited the viability of pancreatic cancer cells, whereas overexpression of miR-214 decreased the sensitivity of the cells to gemcitabine (GEM). Furthermore, we identified WNT3A and FGF7 as potential targets of miR-15a and ING4 as a target of miR-214.ConclusionsAberrant expression of miRNAs such as miR-15a and miR-214 results in different cellular effects in pancreatic cancer. Downregulation of miR-15a might contribute to proliferation of pancreatic cancer cells, whereas upregulation of miR-214 in pancreatic cancer specimens might be related to the poor response of pancreatic cancer cells to chemotherapy. MiR-15a directly targets multiple genes relevant in pancreatic cancer, suggesting that it may serve as a novel therapeutic target for treatment of the disease.

show abstract

Section: Resultsmentioning

confidence: 99%

Dysregulation of miR-15a and miR-214 in human pancreatic cancer

et al. 2010

View full text Add to dashboard Cite

show abstract

“…The combination of gemcitabine and mitomycin C was studied by Tuinmann et al in a trial involving 55 patients with advanced pancreatic cancer [27]. These patients were given gemcitabine 800 mg/m 2 intravenously on days 1, 8 and 15, and mitomycin C 8 mg/m 2 intravenously on day 1 every 4 weeks in an outpatient setting.…”

Section: Clinical Trials Of Gemcitabine Alone or In Combination With mentioning

confidence: 99%

Rationale for an Intraperitoneal Gemcitabine Chemotherapy Treatment for Patients with Resected Pancreatic Cancer

Kamath¹,

Yoo²,

Stuart³

et al. 2009

PRA

View full text Add to dashboard Cite

Currently, the surgical management of pancreas cancer is recognized around the world as inadequate. Long-term survival is rare even though there is a potentially curative R0 resection. There is a strong rationale for the use of chemotherapy in the operating room to reduce local-regional and hepatic sites of recurrent/progressive disease. Gemcitabine monotherapy administered by an intraperitoneal route in the operating room with hyperthermia and then for long-term treatment postoperatively has a strong pharmacologic basis. The exposure of peritoneal surfaces to intraperitoneal gemcitabine is approximately 500 times the exposure that occurs within the plasma. By analogy to another lethal disease, ovarian cancer, intraperitoneal gemcitabine chemotherapy used following potentially curative resection is supported. Data that shows a superiority of multiagent chemotherapy to gemcitabine monotherapy has not been reported. A standardized treatment with intraoperative chemotherapy monitoring of gemcitabine would greatly facilitate further improvements in pancreas cancer treatment and lead the way to an evolution of more successful treatment strategies of this dread disease. The aim of this review is to present the recent available medical information and patents applicable to patients with resected pancreatic cancer.

show abstract

“…The combination of gemcitabine and mitomycin C was studied by Tuinmann et al in a trial involving 55 patients with advanced pancreatic cancer [30]. These patients were given gemcitabine 800 mg/m 2 intravenously on days 1, 8, and 15, and mitomycin C 8 mg/m 2 intravenously on day 1 every 4 weeks in an outpatient setting.…”

Section: Clinical Trials Of Gemcitabine Alone or In Combination Wimentioning

confidence: 99%

Intraperitoneal Gemcitabine Chemotherapy Treatment for Patients with Resected Pancreatic Cancer: Rationale and Report of Early Data

Sugarbaker¹,

Stuart²,

Bijelić³

2011

International Journal of Surgical Oncology

View full text Add to dashboard Cite

Currently, the surgical management of pancreas cancer is recognized around the world as inadequate. Despite a potentially curative R0 resection, long-term survival is rare. There is a strong rationale for the use of chemotherapy in the operating room to reduce local-regional of recurrent/progressive disease. Gemcitabine monotherapy administered by an intraperitoneal route in the operating room with hyperthermia and then for long-term treatment postoperatively has a pharmacologic basis in that the exposure of peritoneal surfaces to intraperitoneal gemcitabine is approximately 200–500 times the exposure that occurs within the plasma. A standardized treatment with intraoperative and long-term chemotherapy that is well tolerated would greatly facilitate further improvements in pancreas cancer treatment and may lead the way to an evolution of more successful treatment strategies of this dread disease. The aim of this paper is to present the early data on a protocol in progress in patients with resected pancreatic cancer.

show abstract

Gemcitabine and mitomycin C in advanced pancreatic cancer: a single-institution experience

Cited by 11 publications

References 22 publications

Dysregulation of miR-15a and miR-214 in human pancreatic cancer

Dysregulation of miR-15a and miR-214 in human pancreatic cancer

Rationale for an Intraperitoneal Gemcitabine Chemotherapy Treatment for Patients with Resected Pancreatic Cancer

Intraperitoneal Gemcitabine Chemotherapy Treatment for Patients with Resected Pancreatic Cancer: Rationale and Report of Early Data

Contact Info

Product

Resources

About